The hidden diversity of antibody heavy chains implications for myasthenia gravis 3919

Abstract Description Acetylcholine receptor (AChR) antibody-positive myasthenia gravis (MG) is an autoimmune disorder leading severe muscle weakness. We hypothesize that these pathogenic antibodies show distinct immunogenomic patterns, including specific usage of variable (V), diversity (D), joining (J), and constant (C) alleles in immunoglobulin heavy chains (IGH). Here, we employed two long-read sequencing Methods IGcapture for high-resolution IGH genotyping and FLAIRR-seq (near Full-Length Adaptive Immune Receptor Repertoire sequencing) to examine IGH expression in AChR-MG (n = 48) and healthy controls (n = 48). FLAIRR-seq revealed significant clonal expansion in IGHG1, IGHG2, and IGHG4 genes in MG individuals. A notable increase in IGHG3 usage was also observed, warranting further examination due to the pathogenic role of IgG3 autoantibodies in AChR-MG. Genes like IGHV1-69 and IGHV3-9 were shown to be used at common frequencies by groups of AChR-MG individuals in IGHG3 repertoires. Moreover, preliminary data identified 70 novel C alleles in AChR-MG versus 44 in healthy controls. Additionally, IGHG3 alleles with truncated hinge regions, associated with elevated complement activity in previous studies were more frequent in AChR-MG individuals. Understanding the genetic diversity, specifically in the C region of IGH, may reveal key residues that mediate complement activation. These discoveries could help identify variants that contribute to disease severity and progression among individuals. Funding Sources Funding from the Myasthenia Gravis Rare Disease Network (“Supported by NIH U54NS115054 and the MGNet.”) Topic Categories Basic Autoimmunity (BA)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2025-11-01
DOI
https://doi.org/10.1093/jimmun/vkaf283.1664
Primary Topic
Myasthenia Gravis and Thymoma
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The hidden diversity of antibody heavy chains implications for myasthenia gravis 3919

Elizabeth Hudson, Easton E. Ford, Oscar L. Rodriguez, Kevin C. O’Connor et al.
The Journal of Immunology
Myasthenia Gravis and Thymoma
article

The hidden diversity of antibody heavy chains implications for myasthenia gravis 3919

Elizabeth Hudson, Easton E. Ford, Oscar L. Rodriguez, Kevin C. O’Connor, L. Y. Young, Corey T. Watson, Melissa Laird Smith, Minh Pham, Soumya S. Yandamuri, Uddalok Jana, Veenasravani Pendyala, Zach VanWinkle
article en

Abstract

Abstract Description Acetylcholine receptor (AChR) antibody-positive myasthenia gravis (MG) is an autoimmune disorder leading severe muscle weakness. We hypothesize that these pathogenic antibodies show distinct immunogenomic patterns, including specific usage of variable (V), diversity (D), joining (J), and constant (C) alleles in immunoglobulin heavy chains (IGH). Here, we employed two long-read sequencing Methods IGcapture for high-resolution IGH genotyping and FLAIRR-seq (near Full-Length Adaptive Immune Receptor Repertoire sequencing) to examine IGH expression in AChR-MG (n = 48) and healthy controls (n = 48). FLAIRR-seq revealed significant clonal expansion in IGHG1, IGHG2, and IGHG4 genes in MG individuals. A notable increase in IGHG3 usage was also observed, warranting further examination due to the pathogenic role of IgG3 autoantibodies in AChR-MG. Genes like IGHV1-69 and IGHV3-9 were shown to be used at common frequencies by groups of AChR-MG individuals in IGHG3 repertoires. Moreover, preliminary data identified 70 novel C alleles in AChR-MG versus 44 in healthy controls. Additionally, IGHG3 alleles with truncated hinge regions, associated with elevated complement activity in previous studies were more frequent in AChR-MG individuals. Understanding the genetic diversity, specifically in the C region of IGH, may reveal key residues that mediate complement activation. These discoveries could help identify variants that contribute to disease severity and progression among individuals. Funding Sources Funding from the Myasthenia Gravis Rare Disease Network (“Supported by NIH U54NS115054 and the MGNet.”) Topic Categories Basic Autoimmunity (BA)

The Journal of ImmunologyVol. 214(Supplement_1)
University of Louisville (US), Yale University (US), University of Louisville Hospital (US)
National Institutes of Health, National Institute of Dental and Craniofacial Research
Openalex Percentile: Top 51%
Myasthenia Gravis and Thymoma
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.